Genmab — April 2019

[Helge_LarsenPI-redaktør]

Pæne store spring op og ned i kurseni slutauktionen.

[iboge]

En dag i plus, 1 kr. pr. aktie, HURRA.

[iboge]

Nu, 1,5 kr,

[E_L]

well we closed the february gap and found a few buyers there and formed a tiny hammer -not that that means a lot with this stock... Let's see if it can hold in the next few days

[Plimsoller]

God morgen

[Parasitism]

God morgen

[Bulder]

Recepttal?

[bibob]

God morgen.

[bibob]

Fik vi ikke dem før påske Bulder. ??

[polle1]

God morgen og god dag

[jkj]

nej det gjorde vi ikke, vi mangler dem for at regne den nøjagtige rabat ud.

[E_L]

"Based on the promising preliminary results and the large interest in treating RRMM patients with melflufen together with daratumumab, Oncopeptides is planning to start a phase 3 study with this combination later this year."
https://finance.yahoo.com/news/oncopeptides-provides-guidance-patient-recruitment-054600203.html

[Sukkeralf]

Exciting to see isatuximab data - and how Sanofi will behave when (if) it gets approved:

[Sukkeralf]

https://iplanner.asco.org/am2019/#/

[E_L]

well, they are already looking for an
Associate Director, Isatuximab Global Marketing, Multiple Myeloma https://www.linkedin.com/jobs/view/associate-director-isatuximab-global-marketing-multiple-myeloma-at-sanofi-1228850133?trk=guest_job_details_job_title

[JohnW]

Hvilken behandlingslinie søges Isatuximab godkendt til?

[kkjoel]

Er recepttallene virkelig ikke kommet endnu?

[kkjoel]

Der plejer altid at være en der er flink til at offentliggøre dem herinde...

[E_L]

@JohnW - it isn't yet , it does have orphan status though in US and Europe. and i think i saw it on the agenda for this weeks EMA meeting for the combo with pom/dex

[JohnW]

Ok, thanks E L.